| |  Online-Ressource |
|---|
| Verfasst von: | Passweg, Jakob R. [VerfasserIn]  |
|---|
| | Baldomero, H. [VerfasserIn] |
|---|
| | Bregni, M. [VerfasserIn] |
|---|
| | Cesaro, S. [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| | Duarte, R. F. [VerfasserIn] |
|---|
| | Falkenburg, J. H. F. [VerfasserIn] |
|---|
| | Kröger, N. [VerfasserIn] |
|---|
| | Farge-Bancel, D. [VerfasserIn] |
|---|
| | Bobby Gaspar, H. [VerfasserIn] |
|---|
| | Marsh, J. [VerfasserIn] |
|---|
| | Mohty, M. [VerfasserIn] |
|---|
| | Peters, C. [VerfasserIn] |
|---|
| | Sureda, A. [VerfasserIn] |
|---|
| | Velardi, A. [VerfasserIn] |
|---|
| | Ruiz de Elvira, C. [VerfasserIn] |
|---|
| | Madrigal, A. [VerfasserIn] |
|---|
| Titel: | Hematopoietic SCT in Europe |
|---|
| Titelzusatz: | data and trends in 2011 |
|---|
| Verf.angabe: | J.R. Passweg, H. Baldomero, M. Bregni, S. Cesaro, P. Dreger, R. F. Duarte, J.H.F. Falkenburg, N. Kröger, D. Farge-Bancel, H. Bobby Gaspar, J. Marsh, M. Mohty, C. Peters, A. Sureda, A. Velardi, C. Ruiz de Elvira and A. Madrigal |
|---|
| E-Jahr: | 2013 |
|---|
| Jahr: | 15 April 2013 |
|---|
| Umfang: | 7 S. |
|---|
| Fussnoten: | Gesehen am 20.12.2021 |
|---|
| Titel Quelle: | Enthalten in: Bone marrow transplantation |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2013 |
|---|
| Band/Heft Quelle: | 48(2013), 9, Seite 1161-1167 |
|---|
| ISSN Quelle: | 1476-5365 |
|---|
| Abstract: | In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries. |
|---|
| DOI: | doi:10.1038/bmt.2013.51 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/bmt.2013.51 |
|---|
| | Volltext: https://www.nature.com/articles/bmt201351 |
|---|
| | DOI: https://doi.org/10.1038/bmt.2013.51 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Bone marrow transplantation |
|---|
| | Therapeutics |
|---|
| K10plus-PPN: | 178258269X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Hematopoietic SCT in Europe / Passweg, Jakob R. [VerfasserIn]; 15 April 2013 (Online-Ressource)
